Table 2 Treatments of lung cancer patients
Treatments n = 112 (100%) | N (%) |
|---|---|
Surgery, n (%) 62 (55) | 62 (100) |
Elective | 60 (97) |
Revision | 3 (5) |
Emergency | 2 (3) |
Radiation (Rad), n (%) 56 (50) | 56 (100) |
Thorax | 45 (80) |
Brain | 14 (25) |
Skeleton | 7 (13) |
Chemotherapy, n (%) 69 (62) | 69 (100) |
Platinum compounds | 58 (84) |
Vinorelbine | 32 (46) |
Pemetrexed | 18 (26) |
Taxanes | 16 (23) |
Etoposide | 9 (13) |
Gemicitabine | 2 (3) |
Bisphosphonates | 11 (16) |
Targeted, n (%) 47 (42) | 47 (100) |
Kinase inhibitors | 15 (32) |
Immune checkpoint inhibitors | 33 (70) |
Viscum album L. (VA), n (%) 53 (47) | 53 (100) |
Subcutaneous | 49 (92) |
Intravenous | 35 (66) |
Intra-tumoural/-pleural | 3 (6) |